Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06551324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06551324 · ClinicalTrials.gov record · last posted 2026-08-11

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Study acronym: MEVPRO-1
StatusActive, Not Recruiting
PhasePhase 3
SponsorPfizer
Started2024-10-21
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Protocol amendment history 4 changes detected by DataLookout

2026-08-12
Trial sites reduced: 230 → 224 locations
2026-08-12
Primary completion pushed: 2026-07-13 → 2026-12-28
2026-05-06
Trial status changed: Recruiting → Active, Not Recruiting
2026-05-06
Trial sites reduced: 233 → 230 locations
Trial Details
NCT Number NCT06551324
Lead Sponsor Pfizer
Conditions Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment 600 participants
Start Date 2024-10-21
Primary Completion 2026-12-28 (estimated)
Study Completion 2028-10-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-11